{"podcast":{"title":"Breast Cancer Update","slug":"breast-cancer-update-757579","podcast_index_feed_id":757579,"rss_url":"https://feeds.captivate.fm/breast-oncology/","website_url":"https://www.researchtopractice.com/browse-by-tumor-types/breast-cancer","image_url":"https://artwork.captivate.fm/ad97e2be-455a-4b53-ab3d-383838c145e5/cbjJP3tyd5NWFP4W5DD1CnhC.png","author":"Dr. Neil Love","episode_count":118,"summary":"Featuring one-on-one interviews conducted by Dr Neil Love, this series bridges the gap between research and patient care by providing medical oncologists, hematologists and hematology-oncology fellows ongoing access to the perspectives and opinions of national and international breast cancer clinical investigators.","last_synced_at":"2026-09-22T02:17:02.774213+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579"},"episode":{"title":"Breast Cancer — Proceedings from a Session Held in Conjunction with the 2026 ASCO Annual Meeting on the Use of Oral SERDs and Agents Targeting the PI3K/AKT/mTOR Pathway","slug":"breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway","published_at":"2026-07-25T13:00:00+00:00","page_url":"https://stenobird.com/podcast/breast-cancer-update-757579/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway","show_page_url":"https://stenobird.com/podcast/breast-cancer-update-757579","url":"https://breast-oncology.captivate.fm/episode/6082-asco2026-serds-pi3k-akt-mtor-bc","audio_url":"https://dts.podtrac.com/redirect.mp3/episodes.captivate.fm/episode/24be6999-4fc0-4ed1-b25e-1e8099f15564.mp3","summary":"Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney, including the following topics: Introduction (0:00) Current and Future Roles of Agents Targeting the PI3K/AKT/mTOR Pathway and Oral Selective Estrogen Receptor Degraders (SERDs) in First-Line Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer (mBC) — Dr Turner (2:35) Role of Oral SERD Monotherapy in the Treatment of Progressive HR-Positive, HER2-Negative mBC — Dr O’Shaughnessy (25:23) Potential Use of Oral SERD-Containing Combination Regimens in Managing Progressive HR-Positive, HER2-Negative mBC — Dr Mayer (46:29) Clinical Utility of Agents Targeting the PI3K/AKT/mTOR Pathway for Patients with Progressive HR-Positive, HER2-Negative mBC — Dr Hurvitz (1:07:06) Potential Use of Oral SERDs for HR-Positive, HER2-Negative Localized Breast Cancer — Dr Tolaney (1:38:17) CME information and select publications","meta_description":"Featuring perspectives from Dr Sara A Hurvitz, Dr Erica Mayer, Dr Joyce O’Shaughnessy, Dr Sara M Tolaney and Dr Nicholas Turner, moderated by Dr Tolaney,…","key_points":[],"chapters":[],"topics":[],"duration_seconds":7096,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/breast-cancer-update-757579/episodes/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/breast-cancer-update-757579/breast-cancer-proceedings-from-a-session-held-in-conjunction-with-the-2026-asco-annual-meeting-on-the-use-of-oral-serds-and-agents-targeting-the-pi3k-akt-mtor-pathway.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}